CL2015002627A1 - Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol - Google Patents

Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol

Info

Publication number
CL2015002627A1
CL2015002627A1 CL2015002627A CL2015002627A CL2015002627A1 CL 2015002627 A1 CL2015002627 A1 CL 2015002627A1 CL 2015002627 A CL2015002627 A CL 2015002627A CL 2015002627 A CL2015002627 A CL 2015002627A CL 2015002627 A1 CL2015002627 A1 CL 2015002627A1
Authority
CL
Chile
Prior art keywords
treatment
compositions
dipiridamol
preferibly
eye disorders
Prior art date
Application number
CL2015002627A
Other languages
English (en)
Inventor
Moshe Rogosnitzky
Original Assignee
Remedeye Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc filed Critical Remedeye Inc
Publication of CL2015002627A1 publication Critical patent/CL2015002627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN DESCRIBE COMPOSICIONES PARA EL USO EN EL TRATAMIENTO DE TRASTORNOS OCULARES, LAS COMPOSICIONES QUE INCLUYEN UNA CANTIDAD EFECTIVA DE UN DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE. PREFERIBLEMENTE, EL DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE ES FORMULADO COMO UNA SOIUCION. PREFERIBLEMENTE, EL DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE ES AL MENOS UN AGENTE SELECCIONADO DEL GRUPO QUE CONSISTENTE DE: DIPIRIDAMOL, Y SU SAL FARMACÉUTICAMENTE ACEPTABLE. PREFERIBLEMENTE, LA CANTIDAD EFECTIVA CORRESPONDE A UNA CONCENTRACIÓN DE POR LO MENOS APROXIMADARNENTE UNA MOLARIDAD DE 10-5. PREFERIBLEMENTE, LA CANTIDAD EFECTIVA SE BASA EN LA ADMINISTRACIÓN DE UN TRATAMIENTO DE AL MENOS UNA VEZ CADA DOS DIAS.
CL2015002627A 2013-03-12 2015-09-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol CL2015002627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compounds for use in ocular disorders using dipyridamole

Publications (1)

Publication Number Publication Date
CL2015002627A1 true CL2015002627A1 (es) 2016-03-11

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002627A CL2015002627A1 (es) 2013-03-12 2015-09-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol

Country Status (14)

Country Link
EP (1) EP2968328A4 (es)
JP (1) JP6820658B2 (es)
KR (2) KR20150126021A (es)
CN (1) CN105188702B (es)
AU (1) AU2014229371B2 (es)
BR (1) BR112015022084A2 (es)
CA (1) CA2905594A1 (es)
CL (1) CL2015002627A1 (es)
EA (1) EA035966B1 (es)
IL (1) IL225179A (es)
MX (1) MX2015012716A (es)
MY (1) MY182591A (es)
SG (2) SG10201706937UA (es)
WO (1) WO2014141079A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180015090A1 (en) * 2015-01-28 2018-01-18 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001805A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations and their methods of preparation
WO2021001806A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
BRPI0618643A2 (pt) * 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation

Also Published As

Publication number Publication date
JP2016514123A (ja) 2016-05-19
EA201591653A1 (ru) 2017-05-31
AU2014229371A1 (en) 2015-10-29
AU2014229371B2 (en) 2018-05-10
EP2968328A1 (en) 2016-01-20
WO2014141079A1 (en) 2014-09-18
CN105188702A (zh) 2015-12-23
MY182591A (en) 2021-01-26
KR20210010638A (ko) 2021-01-27
MX2015012716A (es) 2016-07-06
IL225179A (en) 2017-01-31
EP2968328A4 (en) 2016-11-23
EA035966B1 (ru) 2020-09-07
CN105188702B (zh) 2019-03-26
BR112015022084A2 (pt) 2017-07-18
SG10201706937UA (en) 2017-09-28
JP6820658B2 (ja) 2021-01-27
SG11201507092QA (en) 2015-10-29
CA2905594A1 (en) 2014-09-18
KR20150126021A (ko) 2015-11-10
IL225179A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
CL2019003463A1 (es) Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas.
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний